Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.

Journal of gastrointestinal and liver diseases : JGLD - 1 Sept 2015

Ozaras Resat, Mete Bilgul, Yemisen Mucahit, Balkan Ilker Inanc, Alkan Mustafa, Tabak Fehmi

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Isoquinolines
Share to Carbamates
Share to Imidazoles
Share to Liver Failure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Transplantation

Share to Pyrrolidines

Share to Sulfonamides

Share to Virus Activation

Source

Identifiers

PMID: 26405716

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.PMID 26405716Read ↗

Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program.Semantic proximity Read ↗

Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.Semantic proximity Read ↗

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.Semantic proximity Read ↗

Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.Semantic proximity Read ↗

Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.Semantic proximity Read ↗

Daclatasvir + asunaprevir: first global approval.Semantic proximity Read ↗

Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.Semantic proximity Read ↗

Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.Semantic proximity Read ↗

Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.Semantic proximity Read ↗

Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.Semantic proximity Read ↗

Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.